2′,4′-dihydroxychalcone alleviates inflammatory bowel disease by inhibiting NLRP3 inflammasome and modulating gut microbiota

Key Points

• Inhibition of the nlrp3 inflammasome activation leads to significant anti-inflammatory effects in inflammatory bowel disease.
• The study identified 2',4'-dihydroxychalcone as a promising compound for managing nlrp3-related inflammatory conditions.
• Analysis of how gut microbiota interacts with inflammatory processes highlights the compound's therapeutic potential.
• Further investigation is necessary to explore the full impact of 2',4'-dihydroxychalcone on intestinal health and disease.

Abstract